Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Global Collaborative Comparison of SARS-CoV-2 Antigenicity Across 15 Laboratories.
Brangel P, Tureli S, Mühlemann B, Liechti N, Zysset D, Engler O, Hunger-Glaser I, Ghiga I, Mattiuzzo G, Eckerle I, Bekliz M, Rössler A, Schmitt MM, Knabl L, Kimpel J, Tort LFL, de Araujo MF, de Oliveira ACA, Caetano BC, Siqueira MM, Budt M, Gensch JM, Wolff T, Hassan T, Selvaraj FA, Hermanus T, Kgagudi P, Crowther C, Richardson SI, Bhiman JN, Moore PL, Cheng SMS, Li JKC, Poon LLM, Peiris M, Corman VM, Drosten C, Lai L, Hunsawong T, Rungrojcharoenkit K, Lohachanakul J, Sigal A, Khan K, Thiel V, Barut GT, Ebert N, Mykytyn AZ, Owusu Donkor I, Aboagye JO, Nartey PA, Van Kerkhove MD, Cunningham J, Haagmans BL, Suthar MS, Smith D, Subissi L. Brangel P, et al. Among authors: tort lfl. Viruses. 2024 Dec 18;16(12):1936. doi: 10.3390/v16121936. Viruses. 2024. PMID: 39772242 Free article.
Homologous equivalence study of immunogenicity after third dose of Covid-19 vaccine (recombinant) with an interval of six months after the second dose, comparing the interval of eight and 12 weeks between the first two doses.
Vianna CM, da Silva E Sá GR, Seid MVH, Camacho LAB, Xavier JR, da Gama VC, de Castro TDM, Dos Santos EAP, de Almeida CD, Cruz RLS, Siqueira M, Maia MLS, Ferroco CLV, de Araújo MF, Tort LFL, Caetano BC. Vianna CM, et al. Among authors: tort lfl. Mem Inst Oswaldo Cruz. 2024 Sep 9;119:e240094. doi: 10.1590/0074-02760240094. eCollection 2024. Mem Inst Oswaldo Cruz. 2024. PMID: 39258623 Free PMC article. Clinical Trial.
Comparative analysis of SARS-CoV-2 variants Alpha (B.1.1.7), Gamma (P.1), Zeta (P.2) and Delta (B.1.617.2) in Vero-E6 cells: ultrastructural characterization of cytopathology and replication kinetics.
Vieira DFB, Bandeira DM, da Silva MAN, de Almeida ALT, Araújo M, Machado AB, Tort LFL, Nacife VP, Siqueira MM, Motta FC, Pauvolid-Corrêa A, Barth OM. Vieira DFB, et al. Among authors: tort lfl. Braz J Infect Dis. 2024 Jan-Feb;28(1):103706. doi: 10.1016/j.bjid.2023.103706. Epub 2023 Dec 8. Braz J Infect Dis. 2024. PMID: 38081327 Free PMC article.
Timeline kinetics of protective immunity to SARS-CoV-2 upon primary vaccination and humoral response to variants after booster dose.
da Penha Gomes Gouvea M, Lira Machado KLL, de Oliveira YGP, Moulaz IR, Henriques AG, Gouveia TM, Thompson BP, Lança KEM, de Souza Ramos S, Lacerda GCC, Lenzi JPG, de Castro Pimentel F, Miossi JPM, Rassele ML, Camacho LAB, Villela DAM, de Lima SMB, de Souza Azevedo A, Horbach IS, de Araújo MF, Tort LFL, de Oliveira ACA, Siqueira MM, Garcia CC, da Costa-Rocha IA, Campi-Azevedo AC, Peruhype-Magalhães V, da Silva VG, Miyamoto ST, Dos Santos Fantoni RN, Pinto-Neto LF, Magda Domingues C, de Medeiros Junior NF, Burian AP, Teixeira-Carvalho A, Mota LMH, Mill JG, Martins-Filho OA, Valim V. da Penha Gomes Gouvea M, et al. Among authors: tort lfl. Vaccine. 2023 Oct 20;41(44):6514-6528. doi: 10.1016/j.vaccine.2023.08.022. Epub 2023 Sep 1. Vaccine. 2023. PMID: 37661534
Infectious SARS-CoV-2 Particles from Rectal Swab Samples from COVID-19 Patients in Brazil.
Ribeiro IP, Nascimento LGD, Tort LFL, Pereira EC, Menezes LSR, Malta FC, Oliveira BCEPD, Rodrigues JP, Manso PPA, Pelajo M, Bonaldo MC, Silva PCR, Siqueira MM, Brasil P, Fumian TM. Ribeiro IP, et al. Among authors: tort lfl. Viruses. 2023 May 11;15(5):1152. doi: 10.3390/v15051152. Viruses. 2023. PMID: 37243238 Free PMC article.
Reduced ability to neutralize the Omicron variant among adults after infection and complete vaccination with BNT162b2, ChAdOx1, or CoronaVac and heterologous boosting.
Espíndola OM, Fuller TL, de Araújo MF, Tort LFL, Guaraldo L, Calvet G, Resende P, Bonaldo M, Whitworth J, Smith C, Siqueira M, Brasil P. Espíndola OM, et al. Among authors: tort lfl. Sci Rep. 2023 May 8;13(1):7437. doi: 10.1038/s41598-023-34035-9. Sci Rep. 2023. PMID: 37156846 Free PMC article.
SARS-CoV-2 intra-host diversity, antibody response, and disease severity after reinfection by the variant of concern Gamma in Brazil.
Naveca FG, Nascimento VA, Nascimento F, Ogrzewalska M, Pauvolid-Corrêa A, Araújo MF, Arantes I, Batista ÉR, Magalhães AÁ, Vinhal F, Mattos TP, Riediger I, Debur MDC, Grinsztejn B, Veloso VG, Brasil P, Rodrigues RR, Rovaris DB, Fernandes SB, Fernandes C, Santos JHA, Abdalla LF, Costa-Filho R, Silva M, Souza V, Costa ÁA, Mejía M, Brandão MJ, Gonçalves LF, Silva GA, de Jesus MS, Pessoa K, Corado ALG, Duarte DCG, Machado AB, Zukeram KA, Valente N, Lopes RS, Pereira EC, Appolinario LR, Rocha AS, Tort LFL, Sekizuka T, Itokawa K, Hashino M, Kuroda M, Dezordi FZ, Wallau GL, Delatorre E, Gräf T, Siqueira MM, Bello G, Resende PC. Naveca FG, et al. Among authors: tort lfl. Sci Rep. 2023 May 5;13(1):7306. doi: 10.1038/s41598-023-33443-1. Sci Rep. 2023. PMID: 37147348 Free PMC article.
SARS-CoV-2 variant N.9 identified in Rio de Janeiro, Brazil.
Tort LFL, Ribeiro IP, Menezes LSR, Dos Santos AAC, Santos MP, Damasceno L, Silva PCR, de Siqueira MAMT, Brasil P, Bonaldo MC. Tort LFL, et al. Mem Inst Oswaldo Cruz. 2021 Nov 8;116:e210166. doi: 10.1590/0074-02760210166. eCollection 2021. Mem Inst Oswaldo Cruz. 2021. PMID: 34755818 Free PMC article.
30 results